AARD Aardvark Therapeutics, Inc.
Aardvark Therapeutics, Inc. (AARD) is expected to report earnings on February 12, 2027, after the market close. The consensus earnings estimate is a loss of $0.77 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -20.3% since its last earnings release on November 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Aardvark Therapeutics, Inc.
Aardvark Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The company's lead product candidate includes ARD-101. Aardvark Therapeutics Inc. is based in SAN DIEGO.
Sector
Healthcare
Industry
Biotechnology
Held By 1 ETFs, by dollar flow
Charts powered in part by Lightweight Charts™ by TradingView.